Group 1: Baxter International, Inc. - Baxter International, Inc. is under investigation by Bragar Eagel & Squire, P.C. due to a class action complaint filed on October 16, 2025, alleging misleading statements regarding the Novum LVP device [6] - The complaint claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions and exposed patients to serious risks [6] - Allegations include that Baxter was aware of multiple device malfunctions and that their remedial measures were inadequate, leading to a heightened risk of product withdrawal and sales suspension [6] Group 2: Molina Healthcare, Inc. - Molina Healthcare, Inc. is also being investigated following a class action complaint filed on October 3, 2025, which alleges misleading statements about the company's business and operations [6] - The complaint highlights undisclosed adverse facts regarding Molina's medical cost trend assumptions and a dislocation between premium rates and medical costs [6] - It is claimed that Molina's growth was dependent on limited utilization of various health services, and that financial guidance for fiscal year 2025 was likely to be cut as a result [6]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and October 29, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is claimed that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to October 29, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - There is a deadline of December 15, 2025, for investors to apply to be appointed as lead plaintiff in the lawsuit [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - Baxter International Inc. is facing a federal securities class action due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint claims that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, causing the stock to drop by 22.4%, closing at $21.76 on the same day [4]. - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit against Baxter [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP medical device, which has been linked to serious malfunctions and patient risks [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Baxter between February 23, 2022, and October 29, 2025, to discuss their legal rights [1]. - There is a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [6]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions that could lead to serious injury or death [4]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [4]. - The company's statements regarding the safety and efficacy of the Novum LVPs were claimed to be materially false and misleading [4]. Group 3: Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7] - The lawsuit covers individuals who purchased Baxter common stock between February 23, 2022, and October 29, 2025, with a deadline of December 15, 2025, for investors to apply as lead plaintiffs [7] Allegation Details - The complaint claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3] - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3] - The lawsuit suggests that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for further information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across state and federal courts [5]

Core Viewpoint - The complaint against Baxter International alleges violations of federal securities laws due to misleading statements regarding the Novum LVP, which suffered systemic defects leading to serious patient risks [2]. Group 1: Allegations and Defects - The Novum LVP experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [2]. - The company's attempts to remedy the situation through customer alerts were deemed insufficient as design flaws persisted, continuing to harm patients [2]. Group 2: Impact on Business Operations - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [2]. Group 3: Market Reaction - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in stock price, closing at $21.76 on the same day [3].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant awareness of the issues [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to October 29, 2025, with a deadline for shareholders to register by December 15, 2025 [3][4]. - Shareholders who purchased shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]